Vanguard Group Inc. Sells 2,181,496 Shares of Indivior PLC $INDV

Vanguard Group Inc. reduced its position in shares of Indivior PLC (NASDAQ:INDV) by 38.6% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 3,465,813 shares of the company’s stock after selling 2,181,496 shares during the quarter. Vanguard Group Inc.’s holdings in Indivior were worth $83,104,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Two Seas Capital LP grew its holdings in Indivior by 0.4% in the 2nd quarter. Two Seas Capital LP now owns 11,407,795 shares of the company’s stock valued at $168,151,000 after buying an additional 41,018 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Indivior by 18.4% in the first quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock valued at $79,757,000 after acquiring an additional 1,299,425 shares during the period. Rubric Capital Management LP boosted its position in shares of Indivior by 31.6% in the second quarter. Rubric Capital Management LP now owns 4,647,179 shares of the company’s stock valued at $68,499,000 after acquiring an additional 1,117,140 shares during the period. Jefferies Financial Group Inc. grew its stake in shares of Indivior by 47.9% in the second quarter. Jefferies Financial Group Inc. now owns 2,190,274 shares of the company’s stock valued at $32,544,000 after acquiring an additional 708,941 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Indivior by 1,122.6% in the second quarter. Geode Capital Management LLC now owns 1,576,915 shares of the company’s stock valued at $23,244,000 after acquiring an additional 1,447,939 shares in the last quarter. 60.33% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on INDV. Zacks Research cut shares of Indivior from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 13th. HC Wainwright raised their target price on shares of Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Northland Securities set a $50.00 price target on shares of Indivior in a research report on Tuesday, January 20th. Morgan Stanley reiterated an “overweight” rating and issued a $36.00 price target on shares of Indivior in a research note on Wednesday, December 3rd. Finally, Weiss Ratings upgraded Indivior from a “hold (c)” rating to a “buy (b-)” rating in a research note on Monday. Six investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, Indivior has a consensus rating of “Moderate Buy” and a consensus price target of $39.33.

Indivior Trading Down 0.3%

Shares of NASDAQ:INDV opened at $32.05 on Friday. The firm has a 50 day moving average of $34.19 and a 200-day moving average of $30.23. Indivior PLC has a 12 month low of $8.64 and a 12 month high of $38.00. The stock has a market capitalization of $4.01 billion, a PE ratio of 19.54 and a beta of 0.83.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.17. Indivior had a net margin of 16.85% and a negative return on equity of 148.76%. The business had revenue of $358.00 million for the quarter, compared to analysts’ expectations of $305.62 million. On average, research analysts predict that Indivior PLC will post 1.22 EPS for the current fiscal year.

Insider Transactions at Indivior

In other Indivior news, Director Daniel A. Ninivaggi purchased 775 shares of the firm’s stock in a transaction dated Monday, January 5th. The shares were bought at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the purchase, the director owned 16,923 shares in the company, valued at approximately $598,904.97. This trade represents a 4.80% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David E. Wheadon purchased 1,771 shares of the stock in a transaction dated Monday, January 5th. The shares were acquired at an average cost of $35.39 per share, with a total value of $62,675.69. Following the acquisition, the director directly owned 14,395 shares in the company, valued at $509,439.05. This represents a 14.03% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have acquired 4,871 shares of company stock worth $172,385.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.